AGC and RoosterBio partner for cell and exosome therapy manufacturing
Pharmaceutical Technology
AUGUST 17, 2022
This approach will aid in creating an end-to-end solution for developing and producing human mesenchymal stem/stromal cell (hMSC) and exosome therapies. Its network of sites extends access to the newest cell therapy technologies and processes, including allogenic and autologous systems and methods.
Let's personalize your content